Drug Trial Radar · NCT02861534
A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
Last checked: Nov 20, 2026Latest source record: Nov 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,050
Actual
Start
Sep 20, 2016
Primary completion
Jun 18, 2019
Study completion Sep 2, 2019
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Bayer; Canadian VIGOUR Centre; Duke Clinical Research Institute
- First posted
- Aug 10, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with heart failure with reduced ejection fraction (HFrEF). The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF.
Conditions
- Heart Failure
- Chronic Heart Failure With Reduced Ejection Fraction
Interventions
VericiguatDrug
2.5, 5.0, or 10.0 mg orally once daily
Placebo for vericiguatDrug
2.5, 5.0, or 10.0 mg orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) HospitalizationTime frame: Up to approximately 33 months (through primary analysis database cutoff date of 18-June-2019)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.